Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Psybio Therapeutics Corp (OP: PSYBF )

0.0210 +0.0209 (+20900.00%)
Streaming Delayed Price Updated: 2:08 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Psybio Therapeutics Corp

MA, FL And OH Psychedelics Scientists And Educators' Latest Research And Views
Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances... 
Via Benzinga
EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental... 
Via Benzinga
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers 
Via Benzinga
Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom
Psychedelic therapeutics biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed three additional U.S. 
Via Benzinga
Psychedelics Production Methods Expect Further IP Protection With 4 New Patents
Biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed four new U.S. Patent Cooperation Treaty (PCT) applications aiming to convert five provisional patent applications.  
Via Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
PsyBio Therapeutics Reports Interim Third Quarter 2022 Financial Results
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) reported its unaudited interim financial results for the three and nine-month period ended September 30, 2022. 
Via Benzinga
Yeast Produces Bread And Psilocybin, This Company Is Moving Into Clinical Trial Phase
The current clinical scenario sets psilocybin as one of the most advanced psychedelics, expected to become legally approved in the US sometime between the 2023-2024 period and to become available as of... 
Via Benzinga
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database. 
Via Benzinga
DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF), a biotech developing medicines based on naturally-occurring psychedelic substances, and mushroom producer Red Light Holland Corp. (OTC Pink: TRUFF)... 
Via Benzinga
PsyBio Therapeutics Presents "How Genetically Modified Bacteria Can Yield Best-In-Class Psychedelics" At The Psychedelic Capital Conference
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cannabis Movers & Shakers: Burns & Levinson, Water Ways, Chill Brands, Rubicon Organics
Burns & Levinson Expands National Cannabis Business Law Practice Boston-based Burns & Levinson LLP annou... 
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
The Week In Psychedelics: 
Via Benzinga
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.